TCT 273: DanGer Shock-Like Profile Predicts the Outcome of Patients With ST-Elevation Myocardial Infarction Related Cardiogenic Shock

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Edwards Lifesciences; Abiomed; Boston Scientific Corporation; AstraZenca; Bristol-Myers Squibb; Bayer AG; Sanofi-Aventis; Medtronic; Novartis